A recent study demonstrated that the deletion of hepatic Pparα in mice results in enhanced liver steatosis because of the impaired oxidation of FFA [30], underscoring the relevance and potential of hepatocyte PPARα as a drug target for NAFLD. The gene discussed is PPARA; the disease is Hepatic steatosis.